Resveratrol attenuates the progress of liver fibrosis via the Akt/nuclear factor-κB pathways

Zhang,Hui; Sun,Qingfeng; Xu,Tingyan; Hong,Liang; Fu,Rongquan; Wu,Jinguo; Ding,Jiguang

doi:10.3892/mmr.2015.4497

Resveratrol attenuates the progress of liver fibrosis via the Akt/nuclear factor-κB pathways

Authors:
- Hui Zhang
- Qingfeng Sun
- Tingyan Xu
- Liang Hong
- Rongquan Fu
- Jinguo Wu
- Jiguang Ding
View Affiliations

Affiliations: Department of Infectious Diseases, The Third Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325200, P.R. China
Published online on: November 2, 2015 https://doi.org/10.3892/mmr.2015.4497
Pages: 224-230

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver fibrosis is a wound-healing response to chronic liver injury that results in the accumulation of extracellular matrix proteins. It eventually leads to cirrhosis of the liver and liver failure, and it is a critical threat to the health and lives of patients with chronic liver diseases. No effective treatment is currently available. Resveratrol is a polyphenol with antioxidant, anti‑cancer and anti‑inflammatory properties. It has been reported that resveratrol prevents liver fibrosis, possibly by inhibiting NF‑κB activation. The present study investigated the mechanisms by which resveratrol prevented liver fibrosis, focusing on the possible involvement of the NF‑κB pathway. Mice with carbon tetrachloride (CCl4)‑induced liver fibrosis were treated with various concentrations of resveratrol. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and tumor necrosis factor (TNF)‑α were detected by ELISAs. Expression of α‑smooth muscle actin (α‑SMA), collagen I, inhibitor of NF‑κB (IκB) and NF‑κB were detected by western blot analysis. In addition, the present study examined the effects of resveratrol on the expression of fibrosis markers in LX‑2 cells. Western blot analysis was further used to detect the levels of Akt and phosphorylated Akt, as well as the nuclear levels of IκB, phosphorylated IκB and NF‑κB p65. The expression of α‑SMA in resveratrol‑treated LX‑2 cells was detected by immunofluorescence and flow cytometry, which demonstrated that resveratrol decreased the expression of α‑SMA in LX‑2 cells. Resveratrol also decreased CCl4‑induced upregulation of serum AST, ALT, TNF‑α, α‑SMA and collagen I. Finally, resveratrol prevented the activation of NF‑κB and Akt. The results of the present study therefore indicated that resveratrol attenuates liver fibrosis via the Akt/NF-κB pathways.

View Figures

View References

1	Moreira RK: Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med. 131:1728–1734. 2007.PubMed/NCBI
2	Bataller R and Brenner DA: Liver fibrosis. J Clin Invest. 115:209–218. 2005. View Article : Google Scholar : PubMed/NCBI
3	Svegliati-Baroni G, De Minicis S and Marzioni M: Hepatic fibrogenesis in response to chronic liver injury: Novel insights on the role of cell-to-cell interaction and transition. Liver Int. 28:1052–1064. 2008. View Article : Google Scholar : PubMed/NCBI
4	Hernandez-Gea V and Friedman SL: Pathogenesis of liver fibrosis. Annu Rev Pathol. 6:425–456. 2011. View Article : Google Scholar
5	Schuppan D and Kim YO: Evolving therapies for liver fibrosis. J Clin Invest. 123:1887–1901. 2013. View Article : Google Scholar : PubMed/NCBI
6	Friedman SL: Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol. 7:425–436. 2010. View Article : Google Scholar : PubMed/NCBI
7	Baur JA and Sinclair DA: Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov. 5:493–506. 2006. View Article : Google Scholar : PubMed/NCBI
8	Bishayee A, Darvesh AS, Politis T and McGory R: Resveratrol and liver disease: From bench to bedside and community. Liver Int. 30:1103–1114. 2010. View Article : Google Scholar : PubMed/NCBI
9	Bishayee A, Politis T and Darvesh AS: Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev. 36:43–53. 2010. View Article : Google Scholar
10	Raj P, Louis XL, Thandapilly SJ, Movahed A, Zieroth S and Netticadan T: Potential of resveratrol in the treatment of heart failure. Life Sci. 95:63–71. 2014. View Article : Google Scholar
11	Petro TM: Regulatory role of resveratrol on Th17 in autoimmune disease. Int Immunopharmacol. 11:310–318. 2011. View Article : Google Scholar
12	Ndiaye M, Philippe C, Mukhtar H and Ahmad N: The grape antioxidant resveratrol for skin disorders: Promise, prospects and challenges. Arch Biochem Biophys. 508:164–170. 2011. View Article : Google Scholar : PubMed/NCBI
13	Ciddi V and Dodda D: Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies. Pharmacol Rep. 66:799–803. 2014. View Article : Google Scholar : PubMed/NCBI
14	Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR and Kim AL: Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol. 224:274–283. 2007. View Article : Google Scholar : PubMed/NCBI
15	Bujanda L, García-Barcina M, Gutiérrez-de Juan V, Bidaurrazaga J, de Luco MF, Gutiérrez-Stampa M, Larzabal M, Hijona E, Sarasqueta C, Echenique-Elizondo M and Arenas JI: Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterol. 6:352006. View Article : Google Scholar : PubMed/NCBI
16	Kasdallah-Grissa A, Mornagui B, Aouani E, Hammami M, El May M, Gharbi N, Kamoun A and El-Fazaâ S: Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver. Life Sci. 80:1033–1039. 2007. View Article : Google Scholar : PubMed/NCBI
17	Heeboll S, Thomsen KL, Pedersen SB, Vilstrup H, George J and Grønbæk H: Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol. 6:188–198. 2014. View Article : Google Scholar : PubMed/NCBI
18	Choi YJ, Suh HR, Yoon Y, Lee KJ, Kim DG, Kim S and Lee BH: Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase. Arch Pharm Res. 37:1169–1176. 2014. View Article : Google Scholar : PubMed/NCBI
19	Chavez E, Reyes-Gordillo K, Segovia J, Shibayama M, Tsutsumi V, Vergara P, Moreno MG and Muriel P: Resveratrol prevents fibrosis, NF-kappaB activation and TGF-beta increases induced by chronic CCl4 treatment in rats. J Appl Toxicol. 28:35–43. 2008. View Article : Google Scholar
20	Hong SW, Jung KH, Zheng HM, Lee HS, Suh JK, Park IS, Lee DH and Hong SS: The protective effect of resveratrol on dimethylnitrosamine-induced liver fibrosis in rats. Arch Pharm Res. 33:601–609. 2010. View Article : Google Scholar : PubMed/NCBI
21	Sener G, Toklu HZ, Sehirli AO, Velioğlu-Oğünç A, Cetinel S and Gedik N: Protective effects of resveratrol against acetaminophen-induced toxicity in mice. Hepatol Res. 35:62–68. 2006. View Article : Google Scholar : PubMed/NCBI
22	Kasdallah-Grissa A, Mornagui B, Aouani E, Hammami M, Gharbi N, Kamoun A and El-Fazaa S: Protective effect of resveratrol on ethanol-induced lipid peroxidation in rats. Alcohol Alcohol. 41:236–239. 2006. View Article : Google Scholar : PubMed/NCBI
23	Andrade JM, Paraíso AF, de Oliveira MV, Martins AM, Neto JF, Guimarães AL, de Paula AM, Qureshi M and Santos SH: Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition. 30:915–919. 2014. View Article : Google Scholar : PubMed/NCBI
24	Sun B and Karin M: NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene. 27:6228–6244. 2008. View Article : Google Scholar : PubMed/NCBI
25	Abergel A, Sapin V, Dif N, Chassard C, Darcha C, Marcand-Sauvant J, Gaillard-Martinie B, Rock E, Dechelotte P and Sauvant P: Growth arrest and decrease of alpha-SMA and type I collagen expression by palmitic acid in the rat hepatic stellate cell line PAV-1. Dig Dis Sci. 51:986–995. 2006. View Article : Google Scholar : PubMed/NCBI
26	Luedde T and Schwabe RF: NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 8:108–118. 2011. View Article : Google Scholar : PubMed/NCBI
27	Wang F, Liu S, Du T, Chen H, Li Z and Yan J: NF-κB inhibition alleviates carbon tetrachloride-induced liver fibrosis via suppression of activated hepatic stellate cells. Exp Ther Med. 8:95–99. 2014.PubMed/NCBI
28	Matsuda S, Kobayashi M and Kitagishi Y: Roles for PI3K/AKT/PTEN pathway in cell signaling of nonalcoholic fatty liver disease. ISRN Endocrinol. 2013:4724322013. View Article : Google Scholar : PubMed/NCBI
29	Weichhart T and Süemann MD: The PI3K/Akt/mTOR pathway in innate immune cells: Emerging therapeutic applications. Ann Rheum Dis. 67(Suppl 3): iii70–iii74. 2008. View Article : Google Scholar : PubMed/NCBI
30	Jackson LN, Larson SD, Silva SR, Rychahou PG, Chen LA, Qiu S, Rajaraman S and Evers BM: PI3K/Akt activation is critical for early hepatic regeneration after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol. 294:G1401–G1410. 2008. View Article : Google Scholar : PubMed/NCBI